10x Genomics, Inc. 8-K

What Happened

• 10x Genomics, Inc. announced preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. The company issued a press release on January 11, 2026 and furnished that release on Form 8-K filed January 12, 2026 (Exhibit 99.1).

Key Details

• Event type: Item 2.02 — Results of Operations and Financial Condition (preliminary, unaudited results).
• Period covered: Fourth quarter and fiscal year ended December 31, 2025.
• Press release date: January 11, 2026; Form 8-K filed: January 12, 2026.
• Filing signed by Randy Wu, General Counsel and Secretary; press release attached as Exhibit 99.1.

Why It Matters

• Preliminary results can move the stock and influence short-term investor sentiment because they provide the first public quantified view of revenue, earnings or other key metrics for the quarter and year.
• The figures are described as preliminary and unaudited, so investors should expect final, possibly adjusted, numbers in subsequent SEC filings (e.g., 10-K or 10-Q) after audit or review.
• Investors should review the attached press release for the specific revenue, earnings or guidance details and monitor forthcoming filings for audited results and management commentary.